ASML reports transactions under its current share buyback program ASML reports transactions under its current share buyback program VELDHOVEN, the Netherlands – ASML Holding N.V. (ASML) reports the following transactions, conducted under ASML's current share buyback program. DateTotal repurchased sharesWeighted average priceTotal repurchased value08-Dec-25 37,576 €962.62 €36,171,308 09-Dec-25 37,838 €955.96 €36,171,562 10-Dec-25 37,860 €955.40 €36,171,421 11-Dec-25 38,288 €944.71 €36,170,938 12-Dec-25 38,329 €943.72 €36,171,668 ASML’s current share buyback program was announced ...
For access to the full note, please contact Naresh Chouhan ( ) With EU Pharma (ex-Novo) now having reached decade high valuations vs EuroStoxx600, we believe the sector has broken out & the sustainability of the growth profile will now generate continued strong performance. Consensus 5yr sales & EPS CAGR’s stand at 4% & 7% for 15x 2026 PE. We show there is upside to this from underestimated pipelines where cons. rarely fully models “monster” drugs & from M&A which we expect to be strong at JPM ...
ASML reports transactions under its current share buyback program ASML reports transactions under its current share buyback program VELDHOVEN, the Netherlands – ASML Holding N.V. (ASML) reports the following transactions, conducted under ASML's current share buyback program. DateTotal repurchased sharesWeighted average priceTotal repurchased value01-Dec-25 39,527 €915.08 €36,170,185 02-Dec-25 38,518 €939.05 €36,170,216 03-Dec-25 37,709 €959.19 €36,169,986 04-Dec-25 37,502 €964.47 €36,169,723 05-Dec-25 37,625 €961.33 €36,170,019 ASML’s current share buyback program was announced on 10 Nove...
A director at ASML Holding N.V. sold 700 shares at 975.000EUR and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
UCB presented detailed results of the positive phase 3 GEMZ study with Fintepla in CDKL5 deficiency disorder (CDD). The drug showed an estimated 52.7% median reduction in countable motor seizure frequency (CMSF) compared with placebo during a 14 week titration and maintenance period and a favourable safety profile. We view this as highly encouraging in this refractory epilepsy population. Given the infantile onset of CDD, we will be curious to see as of which age, patients could be included in t...
Today, we are publishing the Semicap Equipment section of our 29th Tech Infrastructure Quarterly Bible. The Tech Bible is a must-read for any tech investor, as it summarizes the quarterly earnings reports from the over 140 companies we track, providing an update on our key perspectives and convictions. In the coming weeks we will publish sections on Automotive, Hyperscale & Cloud, Telecom Equipment, Industrials, PCs, Enterprise IT, and Foundry. 3Q25 semicap revenues were flat QoQ, with China up...
UCB announced an additional upgrade to its FY25 financial guidance, where it now expects revenue to exceed € 7.6b, representing +24% y/y (previously at least € 7b), and adj. EBITDA margin to be higher than 31% (previously at least 30%). This is the company's second guidance upgrade this year and shows that UCB's commercial momentum continues its upward trajectory supported by its 5 key growth drivers, including lead product Bimzelx which saw strong momentum in HS, as well as a favourable payer m...
ASML reports transactions under its current share buyback program ASML reports transactions under its current share buyback program VELDHOVEN, the Netherlands – ASML Holding N.V. (ASML) reports the following transactions, conducted under ASML's current share buyback program. DateTotal repurchased sharesWeighted average priceTotal repurchased value24-Nov-2542,618€848.71€36,170,12225-Nov-2541,979€861.61€36,169,64826-Nov-2540,514€892.77€36,169,66827-Nov-2540,165€900.52€36,169,37428-Nov-2540,304€897.42€36,169,442 ASML’s current share buyback program was announced on 10 November 2022, and detai...
ASML's 3Q25 update signals a more optimistic outlook for 2026 than previously anticipated. Recent announcements of major AI investments reinforce the robust long-term prospects for semiconductor capital expenditures. We expect ongoing increases in lithography intensity, positioning ASML for growth that outpaces the broader industry. Reflecting these positive trends, we reiterate our BUY rating and raise our target price to €1,050 (up from €800).
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.